相关实验视频
Updated: Jul 16, 2025

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
欧瑞安型基基基基化物作为一种新型的免疫调节剂类别,具有介质素-17A抑制活性
Xin Tang1,2, Chuanxi Wang3, Lei Wang4,5
1Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai 519000, China.
研究人员对天然化合物进行了选,以检测它们是否抑制了INTERLEUKIN (IL) -17A. 他们从一种真菌中发现了金类型的基基基基,其中化合物3在疾病模型中显示出强大的IL-17A抑制和治疗潜力.
科学领域:
- 自然产品化学 自然产品化学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 干白素 (IL) -17A是一种关键的促炎细胞因子,与许多免疫疾病有关.
- 鉴定IL-17A的新型抑制剂对于开发新的治疗策略至关重要.
- 传统中医成分和微生物代谢产物是生物活性化合物的丰富来源.
研究的目的:
- 为了选显示Interleukin (IL) -17A抑制活性的化合物.
- 识别和描述在IL-17A介导疾病中具有潜在治疗应用的新型天然产品.
主要方法:
- 对传统中医药成分和微生物二次代谢物进行大规模查.
- 在Th17-priming条件下利用IL-17A-GFP记者小鼠的脏细胞.
- 孤立化合物的隔离,鉴定和生物活性评估,包括体内动物模型.
主要成果:
- 来自*Myrothecium gramineum*的奥雷安类型的四烯四化物显示出显著的IL-17A抑制活性.
- 他们分离了9种新的A-I和2种已知化合物.
- 化合物3在疾病模型中表现出强大的剂量依赖IL-17A生成的抑制,抑制糖分解和改善免疫病理.
结论:
- 欧瑞安类型的基基基化物代表了一种针对IL-17A的新型免疫调节剂类.
- 化合物3在治疗IL-17A介导的免疫疾病,如实验性自身免疫脑膜炎和肺高血压方面显示出显著的治疗前景.
- 这项研究强调了真菌代谢物的潜力,作为开发新抗炎药物的来源.
更多相关视频
相关概念视频
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Tumor Immunotherapy
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

